These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28688982)

  • 1. The effects of striatal silent lacunar infarction on the substantia nigra and movement disorders in Parkinson's disease: A follow-up study.
    Zhang G; Zhang C; Zhang Y; Wang Y; Nie K; Zhang B; Xie H; Lu J; Wang L
    Parkinsonism Relat Disord; 2017 Oct; 43():33-37. PubMed ID: 28688982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal silent lacunar infarction is associated with changes to the substantia nigra in patients with early-stage Parkinson's disease: A diffusion kurtosis imaging study.
    Zhang G; Zhang Y; Zhang C; Wang Y; Ma G; Nie K; Xie H; Liu J; Wang L
    J Clin Neurosci; 2016 Nov; 33():138-141. PubMed ID: 27499120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is hyperhomocysteinemia associated with the structural changes of the substantia nigra in Parkinson's disease? A two-year follow-up study.
    Zhang G; Zhang C; Wang Y; Wang L; Zhang Y; Xie H; Lu J; Nie K
    Parkinsonism Relat Disord; 2019 Mar; 60():46-50. PubMed ID: 30316729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson's disease: diffusion kurtosis imaging and the correlation with clinical manifestations].
    Sun YQ; Zhang Q; Jiang Z; Zhang CY; Zhang JW; Chen H; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(45):3534-3537. PubMed ID: 29275590
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution diffusion tensor-imaging indicates asymmetric microstructural disorganization within substantia nigra in early Parkinson's disease.
    Knossalla F; Kohl Z; Winkler J; Schwab S; Schenk T; Engelhorn T; Doerfler A; Gölitz P
    J Clin Neurosci; 2018 Apr; 50():199-202. PubMed ID: 29366621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
    Su D; Gan Y; Zhang Z; Cui Y; Zhang Z; Liu Z; Wang Z; Zhou J; Sossi V; Stoessl AJ; Wu T; Jing J; Feng T
    Mov Disord; 2023 Apr; 38(4):616-625. PubMed ID: 36799459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axonal degeneration in Parkinson's disease - Basal ganglia circuitry and D2 receptor availability.
    Pelzer EA; Melzer C; Schönberger A; Hess M; Timmermann L; Eggers C; Tittgemeyer M
    Neuroimage Clin; 2019; 23():101906. PubMed ID: 31254937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra.
    Skorpil M; Söderlund V; Sundin A; Svenningsson P
    J Parkinsons Dis; 2012; 2(2):171-80. PubMed ID: 23939442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.
    Langley J; Huddleston DE; Merritt M; Chen X; McMurray R; Silver M; Factor SA; Hu X
    Hum Brain Mapp; 2016 Jul; 37(7):2547-56. PubMed ID: 27029026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease.
    Prakash BD; Sitoh YY; Tan LC; Au WL
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1029-33. PubMed ID: 22705126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.